APLS - Apellis Pharmaceuticals Inc Stock Price, Fair Value and News

$18.19+0.03 (+0.17%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

APLS Price Action

Last 7 days

-3.2%

Last 30 days

-25.5%

Last 90 days

-39.2%

Trailing 12 Months

-62.1%

APLS RSI Chart

APLS Valuation

Market Cap

2.3B

Price/Earnings (Trailing)

-11.54

Price/Sales (Trailing)

2.92

EV/EBITDA

-11.87

Price/Free Cashflow

-25.87

APLS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

APLS Fundamentals

APLS Revenue

Revenue (TTM)

781.4M

Rev. Growth (Yr)

45.19%

Rev. Growth (Qtr)

7.98%

APLS Earnings

Earnings (TTM)

-197.9M

Earnings Growth (Yr)

58.96%

Earnings Growth (Qtr)

36.72%

APLS Profitability

EBT Margin

-25.18%

Return on Equity

-86.58%

Return on Assets

-22.36%

Free Cashflow Yield

-3.87%

APLS Investor Care

Shares Dilution (1Y)

4.09%

Diluted EPS (TTM)

-1.59

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	524.1M	628.8M	715.2M	781.4M
2023	105.9M	184.5M	272.9M	396.6M
2022	80.9M	96.6M	113.0M	75.4M
2021	204.6M	158.6M	112.6M	66.6M
2020	6.5M	6.1M	128.4M	250.6M
2019	3.5M	4.0M	4.6M	5.1M
2018	1.6M	0	0	3.0M
2017	0	0	0	277.8K

Get all data in R, Python etc through our Historical Stock Data APIs

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

CEO	Dr. Cedric Francois M.D., Ph.D.
WEBSITE	apellis.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	767

Apellis Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Apellis Pharmaceuticals Inc? What does APLS stand for in stocks?

APLS is the stock ticker symbol of Apellis Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Apellis Pharmaceuticals Inc (APLS)?

As of Thu Apr 17 2025, market cap of Apellis Pharmaceuticals Inc is 2.28 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APLS stock?

You can check APLS's fair value in chart for subscribers.

Is Apellis Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether APLS is over valued or under valued. Whether Apellis Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Apellis Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APLS.

What is Apellis Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 17 2025, APLS's PE ratio (Price to Earnings) is -11.54 and Price to Sales (PS) ratio is 2.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APLS PE ratio will change depending on the future growth rate expectations of investors.